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Protein interaction networkAbstract Several reports document the role of tumor necrosis factor alpha (TNF-a) and lipid
metabolism in the context of acute inflammation as a causative factor in obesity-associated insulin
resistance and as one of the causative parameter of type 2 diabetes mellitus (T2DM). Our aim was
to investigate the association between 308G/A and 238G/A polymorphisms located in the pro-
moter region of the TNF-a gene in T2DM in the Indian population with bioinformatics analysis of
TNF-a protein networking with an aim to find new target sites for the treatment of T2DM. Demo-
graphics of 100 diabetes patients and 100 healthy volunteers were collected in a structured proforma
and 3 ml blood samples were obtained from the study group, after approval of Institutional Ethics
Committee of the hospital (IEC). The information on clinical parameters was obtained from med-
ical records. Genomic DNA was extracted; PCR–RFLP was performed using TNF-a primers speci-
fic to detect the presence of SNPs. Various bioinformatics tools such as STRING software were
used to determine its network with other associated genes. The PCR–RFLP studies showed thaterabad
hmad),
ellitus.
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Saudi Journal of Biological Sciences (2016),among the 238G/A types the GG genotype was 87%, GA genotype was 12% and AA genotype
was 1%. Almost a similar pattern of results was obtained with TNF-a 308G/A polymorphism.
The results obtained were evaluated statistically to determine the significance. By constructing
TNF-a protein interaction network we could analyze ontology and hubness of the network to iden-
tify the networking of this gene which may influence the functioning of other genes in promoting
T2DM. We could identify new targets in T2DM which may function in association with TNF-a.
Through hub analysis of TNF-a protein network we have identified three novel proteins RIPK1,
BIRC2 and BIRC3 which may contribute to TNF-mediated T2DM pathogenesis. In conclusion,
our study indicated that some of the genotypes of TNF-a 308G/A, 238G/A were not signifi-
cantly associated to type 2 diabetes mellitus, but TNF-a 308G/A polymorphism was reported
to be a potent risk factor for diabetes in higher age (>45) groups. Also, the novel hub proteins
may serve as new targets against TNF-a T2DM pathogenesis.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent times have witnessed large-scale human genetic studies
that have made dramatic progress in identifying type 2 dia-
betes susceptibility genes, increasing the list from three impor-
tant genes (PPARG, KCNJ11, and TCF7L2) to about more
than 20 other genes in the last 5 years. Diabetes, a chronic
metabolic disorder, that affects >170 million people world-
wide has become one of the leading causes of death and dis-
ability. It has been estimated that by 2030, the number of
affected people would rise to about 366 million (Wild et al.,
2004). Of the two types of diabetes, the majority (90%) is
affected by type 2 diabetes (T2DM), characterized by impaired
insulin secretion from pancreatic beta cells and insulin resis-
tance. As per the estimates reported by Wild et al. (2004) the
three leading countries in terms of the number of individuals
affected by T2DM are India (31.7 million in 2000; 79.4 million
in 2030), China (20.8 million in 2000; 42.3 million in 2030); and
the US (17.7 million in 2000; 30.3 million in 2030). These fig-
ures emphasize that T2DM has become an epidemic in the
21st century, with India in the lead for the largest number of
diabetics in the world.
T2DM is most often associated with older age, obesity,
family history of diabetes, previous history of gestational dia-
betes, physical inactivity and certain ethnicities. About 80% of
people with T2DM are overweight. The long-term complica-
tions in diabetes affect almost every organ of the body. The
disease often leads to retinopathy, nephropathy, heart and
blood vessel disease, amputations and nerve damage. Uncon-
trolled diabetes can complicate pregnancy and cause birth
defects in new-born babies (Singh, 2011).
Earlier T2DM was generally regarded as a disease of the
middle-aged group or elderly, but recent evidences suggest that
even children and adolescents aged less than 30 years are
becoming caught up in the diabetes epidemic, attributed
mainly to the rise in obesity in these groups. Numerous reports
exist of T2DM in children in countries such as Japan, USA,
India, Australia and UK (Bloomgarden, 2004). This scenario
of decrease in the age for the onset of diabetes may be a cause
for concern with grave consequences in terms of resources and
healthcare, as future generations become afflicted at a younger
age may find their productivity affected. Thus, it has become
pertinent not only to devise preventive measures, but also to
counteract this rising epidemic with new knowledge, or else
find new druggable targets.al., TNF-alpha 308G/A and 238G/A
http://dx.doi.org/10.1016/j.sjbs.2016.05The lifetime risk for type-2 diabetes is 38% if one parent
has diabetes and 60% if both the parents are affected
(Stumvoll et al., 2005). Multiple susceptibility genes have been
reported in pathogenesis of type-2 diabetes and associated
complications such as neuropathy, nephropathy and retinopa-
thy. Current evidence suggests that oxidative stress may be one
of the underlying pathological conditions associated with the
development of pre-diabetic and diabetic conditions and may
also be responsible for the complications of diabetes (Evans
et al., 2002). About 70–80% of all T2DM patients are reported
as obese, the key insights into understanding type 2 diabetes
may be obtained by exploring the mechanisms through which
obesity can bring about insulin resistance in the vital tissues. It
is clear that the molecular etiology of insulin resistance is mul-
tifactorial where numerous independent mechanisms con-
tribute to the final phenotype (Martyn et al., 2008). Several
such molecular targets involved in inhibiting insulin action
have been characterized in recent years (Moller, 1993; Katz
et al., 1995; Hotamisligil, 1999; Arora, 2012).
Since TNF-a is a multifunctional, pro-inflammatory cyto-
kine which plays an important role in several autoimmune dis-
eases like rheumatoid arthritis, pernicious anemia, diabetes
mellitus, etc we hypothesized that TNF-a may be a mediator
of obesity-linked insulin resistance in type 2 diabetes. This is
also supported by studies in human obesity that have shown
an increased adipose production in cases where TNF-a expres-
sion was high. Ethnic differences have also been observed to
contribute to risk of development of T2DM. These reports
support the need to investigate the role of TNF-a in influenc-
ing/or promoting diabetes.
1.1. Tumor necrosis factor alpha (TNF-a) gene
The TNF-a gene is located within the HLA III region in chro-
mosome 6p21 (Wilson et al., 1997; Nishimura et al., 2003)
(Fig. 1).This gene was first isolated by Carswell et al. (1975)
in a study exploring tumor necrosis in sarcoma Meth A. It is
an important pro-inflammatory adipocytokine (Fig. 2,
(Dushay and Abrahamson, 2005)) that is involved in regulat-
ing cellular processes such as differentiation, proliferation
and cell death, as well as in inflammation and immune
responses. It has also been implicated in pathogenesis of many
human diseases (Qidwai and Khan, 2011; Sikka et al., 2014).
TNF is believed to be one of the main pro-inflammatory
cytokines involved in the destruction of pancreatic ß-cellspolymorphisms and its protein network associated with type 2 diabetes mellitus.
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Figure 1 Chromosomal location of TNF-a.
TNF-alpha in Type 2 Diabetes Mellitus 3(Yang et al., 1994; Rabinovitch and Suarez-Pinzon, 1998).
TNF mediated toxicity of ß-cells has been reported to be sup-
ported by other inflammatory cytokines such as interleukin-1
and interferon-c (Yang et al., 1994). Non-obese diabetic mice
that overexpressed TNF-a in their ß-cells were also found to
be predisposed to diabetes (Vaux and Flavell, 2000).
Genetic variations in the promoter region may regulate
TNF-a production, transcription and may influence suscepti-
bility to inflammatory related diseases. Some studies have
examined single nucleotide polymorphisms (SNPs) in the pro-
moter region of the TNF gene, such as 238G/A, 308G/A,
857C/T, and 1031T/C in humans (Feng et al., 2009a).
TNF-a 308G/A single nucleotide polymorphism in the pro-
moter region of TNF was found to increase the expression of
this pro-inflammatory cytokine in culture cells and was posi-
tively associated with risk for T1DM (Feng et al., 2009b;
Nishimura et al., 2003). TNF-a is reported to impair insulin
signal pathways (Peraldi et al., 1996) thus playing a central role
in the development of T2DM. Although a few studies have
focused on the association between TNF-a 308G/A polymor-
phism and T2DM, their results remain unclear, necessitating
the need for further investigations (Feng et al., 2009a;
Sharma et al., 2014). Hence, the aim of our study was to inves-
tigate the association of two key TNF-a promoter polymor-
phisms, 308G/A and 238G/A, as a risk factor in T2DM
patients (Guzma´n-Flores et al., 2011). Further, we analyzed
the networking of this gene using STRING software to find
its association with other genes in influencing the disease pro-
gression. Our investigation also aims to provide new targets
which could be useful in drug discovery.
2. Materials and methods
2.1. Ethics statement
The study protocol was approved by the Ethics Committee
of the Institute (Bhagwan Mahavir Medical Research Cen-Figure 2 Cytokines secreted by adipocytes. Source: http://www.
medscape.org/viewarticle/501569_5 (Dushay andAbrahamson, 2005.
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eminent doctors helped us identify diabetic patients who
matched our selection criteria. Non-diabetic volunteers were
age and sex matched and formed the control group. We
obtained written informed consent from all study partici-
pants for the use of their blood samples for the
investigation.
2.2. Selection of study group
Clinicians identified 100 diabetes patients and we identified 100
healthy volunteers as controls which formed our study group
(200 subjects). Three millilitre blood samples were obtained
from the study group. Demographic details were collected in
a structured pro forma. The patient case details were obtained
from medical records and documented in the excel sheet. The
clinical profile consisted of age, initial diagnosis, social habits,
life style, and medications used.
2.3. Blood sample collection
Three milliliters of venous blood was collected in an EDTA
containing vacutainer tube (Vacuette) from the study group
(100 + 100) of adult patients with T2DM and non-diabetic
controls with informed consent.
2.4. Genomic DNA isolation
Genomic DNA was isolated from blood samples using the pro-
tocol standardized in our laboratory (Jamil et al., 2014). It is a
rapid non-enzymatic method for salting out cellular proteins
with saturated solution and precipitation by dehydration using
the standard Phenol–Chloroform method. This was followed
by lysing RBC using RBC lysis buffer and removal of protein
content by precipitation. The precipitated DNA was sus-
pended in 70% ethanol to remove salts. Finally the DNA
was suspended in Tris buffer and stored at 20 C until used.
The presence of genomic DNA was detected by running the
isolated samples on 1% agarose gel, electrophoresed at 60 V.
A visual quantification of DNA was done using a 100 bp
DNA marker. The DNA was then considered for PCR–RFLP
procedure.
2.5. Polymerase chain reaction–restricted fragment length
polymorphism (PCR–RFLP)
After checking for the purity of DNA, PCR was carried out in
20 ll reactions using standard procedures (Jamil et al., 2014).
The genomic region encompassing the 308G/A polymor-
phism was amplified using the following primers: forward 50-
AGGCAATAGGTTTTGAGGGCCAT-30 and reverse 50-TC
CTCCCTGCTCCGATTCCG-30. The 107 bp PCR product
was digested with NcoI restriction enzyme, according to the
manufacturer’s instructions for RFLP.
To identify the 238G/A polymorphism, we used the fol-
lowing primers: forward 50-AGAAGACCCCCCTCG
GAACC-30 and reverse 50-ATCTGGAGGAAGCGG
TAGTG-30. The PCR product was digested with MspI restric-
tion enzyme, according to the manufacturer’s instructions for
RFLP.polymorphisms and its protein network associated with type 2 diabetes mellitus.
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After restricted digestion the samples were used for RFLP
analysis by standard protocol and the genotypes of various
bps were obtained. These were categorized into homo, hetero
and wild type genotypes and statistically analyzed to determine
the p values.
2.6. Statistical analysis
All the above experiments were repeated in triplicates. The dis-
tribution of the genotype frequencies of TNF-a promoter poly-
morphisms for patients and control subjects were compared
using the chi-squared test; Odds ratio (OR) with respective
confidence interval (95% CI) for disease susceptibility was also
calculated. The observed frequency of polymorphism between
patients and controls were tested for Hardy–Weinberg equilib-
rium (HWE) using the v2 method. The clinical parameters
such as age, sex, BMI, and random sugar levels were correlated
and calculated for patients with different genotypes. Values
were expressed as percentage, mean, and standard deviation.
Fisher’s two tailed test and Pearson’s correlation were used
to evaluate statistical significance and calculate p value of the
parameters tested, all the statistical analysis was done using
SPSS statistical software (18.0, Chicago Illinois). A p-value
of <0.05 was considered significant.
2.7. Bioinformatics analysis
2.7.1. Construction of TNF-a protein–protein interaction
network, analysis of gene ontology and network hub analysis
To understand the networking of TNF-a, we used the
STRING v 9.05 database (Search Tool for the Retrieval of
Interacting Genes/Proteins http://string-db.org/ (Szklarczyk
et al., 2011)) to retrieve interactions pertaining to this gene.
We analyzed interactions pertaining only to Homo sapiens
and restricted the network to 50 additional interactors. We fur-
ther filtered the network to retain only those interactions with
confidence score >0.9 which signifies more than 80% proba-
bility that these interactions may be replicated in KEGG
(Kyoto Encyclopedia of Genes and Genomes) database. Addi-
tionally, we grouped the interactors into five clusters based on
shared similarity/relatedness, using k-means algorithm
(MacQueen, 1967) provided by STRING database. The gene
ontology enrichment of the network interactors was performed
using KOBAS 2.0 server (KEGG Orthology Based Annota-
tion System, http://kobas.cbi.pku.edu.cn/, (Xie et al., 2011)).
We also analyzed the hubness of the network using cytoHubba
plugin (Lin et al., 2008) in Cytoscape visualization software
(Smoot et al., 2011). For hub analysis we chose degree and
betweenness ranking methods to identify proteins that may
be biologically significant, due to their high interconnectivity,
and hence concomitantly may play a role in the disease.Figure 3 Showing age versus disease-in type 2 diabetes.3. Results
3.1. Demographic results
The demographics of the subjects included in this study were
collected using a questionnaire. The details included their
age, sex, start of illness, period of illness, any treatment andPlease cite this article in press as: Jamil, K. et al., TNF-alpha 308G/A and 238G/A
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05family history. A total of 100 patients were randomly included
in this study, out of which 56% were males and 44% were
females. Care was taken to recruit equal number of healthy
volunteers of similar age and sex. We utilized the help of
attending clinicians in the selection of the study group. Inci-
dentally, there were more number of males in the study group.
3.1.1. Age group
In our study, the age group of patients varied from 20–
90 years, of which 8% were in the age group of 20–30 years,
22% in 31–40 years, 39% in 41–50 years, 23% in 51–60 years
and 8% in 61–90 years (Fig. 3). Based on our data, T2DM
was more prevalent in the age group of P41–50 years; this
may be referred to as the susceptible group.
3.2. Random blood sugar level, body mass index and physical
activity
We found that 78% of the patients showed a high body mass
index and 74% of the patients had a high random blood sugar
level. Among these, only 30% of the patients had the habit of
regularly exercising. Based on our data, patients with the high-
est random blood sugar level were mostly obese or over weight
and based on our demographic data might be attributed to
their poor diet control or lack of exercise (Fig. 4).
3.3. Genotyping
DNA extracted from blood samples by standard procedure
(salting out method (Jamil et al., 2014)) was checked for qual-
ity and quantity on 1% agarose gel. After checking for the pur-
ity of DNA, PCR was carried out in 20 ll reactions as
previously described. The genomic region encompassing the
308G/A polymorphism was amplified using the specific pri-
mers and the 107 bp fragment produced was checked on a
2% agarose gel. Amplification of 238G/A promoter poly-
morphism with specific primers yielded a 152 bp PCR product,
which was also visualized on a 2% agarose gel (figure not
shown). A sample gel electrophoresis image is presented in
Fig. 5 depicting results from 308G/A polymorphism analysis.
A 100 bp DNA ladder (Life Technologies) was simultaneously
run on the gels to confirm the PCR product (bps) sizes.
Photographs of gels were scanned and analyzed.polymorphisms and its protein network associated with type 2 diabetes mellitus.
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Figure 4 Showing random blood sugar, body mass index and
physical activity-in T2DM.
Figure 6 Agarose gel (2%) electrophoresis depicting restriction
digestion of TNF-a (308 polymorphism) with Ncol enzyme.
Lanes 2,4,5,6-GG allele digested PCR product (87 bp and 20 bp);
lane 3 undigested PCR product, lane 7 – GA (107 bp, 87 bp and
20 bp), lane 1 DNA marker.
TNF-alpha in Type 2 Diabetes Mellitus 53.3.1. Restriction fragment length polymorphism (RFLP)
Following enzymatic digestion of the PCR product using NcoI
restriction enzyme and incubation at 37 C for 12 h, the TNF-a
(308G/A) PCR–RFLP products were visualized on a 2%
agarose gel. Three types of bands were observed- a complete
NcoI cut representing homozygous TNF-a (308G/G), result-
ing in two fragments of 87 and 20 bp; a partial cut representing
heterozygous TNF-a (308G/A), resulting in three fragments
of 107, 87 and 20 bp; and an uncut 107 bp fragment represent-
ing homozygous TNF-a (308A/A) (Fig. 6).
The MspI digested 238G/A PCR products were of two
types- a complete MspI cut which yielded a 152 bp fragment
and two fragments of 133 and 19 bp for the wild-type allele
(238G/G) and a partial cut representing heterozygous
TNF-a (238G/A), resulting in three fragments of 152, 133
and 28 bp.
Of the 100 diseased individuals genotyped for 308G/A,
the GG genotype was found in 88%, GA genotype in 10%
and AA genotype in 2% of the patients. In the control group
the results were not much different, since we observed GG
genotype in 87%, GA in 12% and AA in 1% of the healthy
individuals (Table 1). The distribution of 238G/A polymor-
phism in cases were as follows: 85% GG, 12% GA, and 1%
AA, whereas in controls it was 87% GG, 13% GA and 2%Figure 5 Agarose gel (2%) electrophoresis showing PCR prod-
ucts of TNF-a gene (308G/A) 100 bp marker; Lanes 1 to 6–
107 bp PCR product.
Please cite this article in press as: Jamil, K. et al., TNF-alpha 308G/A and 238G/A
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05.AA (Table 1). Since a lot of work has been reported on haplo-
types, we did not include the data here.
3.4. Analysis of TNF-a protein interaction network, gene
ontology and hubness: bioinformatics approach
On analysis of TNF-a network, we found that the fifty-one
network proteins were interconnected via 264 interactions.
Through analysis of KEGG pathway ontology of the network
clusters (Fig. 7), we found that the network was significantly
enriched in several essential pathways. We observed that clus-
ter 1 comprised of nine proteins mainly involved in TNF sig-
naling pathway, NFkB signaling pathway and Toll-like
receptor pathway. The fourteen cluster 2 interactors were
found to be enriched in NFkB signaling pathway and apopto-
sis signaling pathway. Our analysis of the twelve proteins of
cluster 3, which included TNF-a, showed a significant enrich-
ment in TNF signaling pathway. We found that cluster 4 was
comprised of eight proteins, mainly interleukins and cell adhe-
sion proteins. Cluster 5 comprised six proteins significantly
enriched in the JAK–STAT signaling pathway.
On analysis of hubness of the network, we found that six
proteins were common to the degree and betweenness methods
and were among the top ten hub proteins in the network.
These included the proteins TNFRSF1A, BIRC2, BIRC3,
TRAF2, RIPK1, and TRAF6. Of these TNFRSF1A, TRAF2
and TRAF6 have been reported earlier in diabetes. Their hub-
ness further validates their biological and hence disease rele-
vance. Further, we have identified three novel hub proteins-
RIPK1, BIRC2 and BIRC3 that are involved in numerous
interactions in the protein network. RIPK1 (cluster 1, Fig. 7)
functions in regulation of TNF-a production on inhibition of
caspases. BIRC2 and BIRC3 (cluster 2; Fig. 7) function in sup-
pression of apoptosis via binding to TNF-a associated recep-
tors, TRAF1 and TRAF2, and they are also involved in
immune response modulation and other cell growth and
development processes. Thus, these three genes may serve aspolymorphisms and its protein network associated with type 2 diabetes mellitus.
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Table 1 TNF-a 308G/A and 238G/A genotype distributions in T2DM patients and controls.
Genotype T2DM n (%) Control n (%) Odds ratio 95% CI p-value
Polymorphism 308G/A
Wild type GG 88 (88%) 87 (87%) 1.09 0.47–2.53 0.83
Heterozygote GA 10 (10%) 12 (12%) 0.81 0.33–1.98 0.65
Homozygote AA 2 (2%) 1 (1%) 0.49 0.04–5.54 0.56
Polymorphism 238G/A
Wild type GG 85 (85%) 87 (87%) 1.18 0.53–2.62 0.68
Heterozygote GA 12 (12%) 13 (13%) 0.91 0.39–2.11 0.83
Homozygote AA 1 (1%) 2 (2%) 0.49 0.44–5.54 0.56
Figure 7 Clustered TNF-a protein interaction network, retrieved from STRING database. TNF-a has been highlighted in red box while
the novel hub proteins BIRC2, BIRC3 and RIPK1 have been highlighted using blue ovals.
6 K. Jamil et al.
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TNF-alpha in Type 2 Diabetes Mellitus 7novel targets in type 2 diabetes mellitus patients with altered/
dysregulated TNF-a.4. Discussion
We have studied two bi-allelic polymorphisms previously iden-
tified in the TNF-a promoter region, which have been consid-
ered to play an important pathogenic role in T2DM, insulin
resistance and obesity (Guzma´n-Flores et al., 2013; Saxena
et al., 2013; Sikka et al., 2014; Wilson et al., 1992). The
308G/A and 238G/A polymorphisms have been associated
with insulin resistance, obesity and T2DM in different ethnic
groups (Guzma´n-Flores et al., 2013; Saxena et al., 2013;
Sikka et al., 2014; Wilson et al., 1992). In this study, interest-
ingly, we did not find any significant correlation between these
polymorphisms and T2DM subjects of South Indian origin.
Cytokines are important mediators of immunity and there is
now convincing evidence that cytokines also play an important
role in the pathogenesis of autoimmunity. TNF-a is pivotal in
host defense against infections and has a major role in autoim-
mune diseases as well. It is also a crucial cytokine for granu-
loma formation. The level of TNF-a varies from individual
to individual and is genetically determined. There are many
biallelic single nucleotide polymorphisms (SNPs) in and
around the TNF-a gene. The G/A polymorphism, which we
studied, is located upstream of the gene at 308 and is known
to influence TNF-a levels. It has been reported that as com-
pared to the TNF-a 308 G-allele, A-allele has a higher tran-
scriptional activity. TNF-a 308 promoter gene polymorphism
has been reported to be associated with several autoimmune
disorders and metabolic syndrome pathogenesis (Hajeer and
Hutchinson, 2000; Sookoian et al., 2005).
Reports on patient cohorts of mean ages 57 years (Hamann
et al., 1995) and 39 years (Altshuler et al., 2000) have stated a
lack of association of 308G/A polymorphism with type 2 dia-
betes. This could be due to the disparities in their study designs
and variations in the genetic background and may also be due
to environmental exposures of the T2DM patients enrolled in
these studies. This may also indicate the involvement of other
genes in T2DM pathogenesis in younger patients. The discrep-
ancies in studies investigating association of TNF-a promoter
polymorphisms with insulin sensitivity may also be ascribed
to the differences in age of the patients in these studies
(Ferna´ndez-Real et al., 1997; Rasmussen et al., 2000).
TNF-a 308G/A single nucleotide polymorphism (SNP) in
the promoter region of TNF was found to increase the expres-
sion of this pro-inflammatory cytokine in culture cells and was
positively associated with risk for T1DM (Wilson et al., 1997;
Feng et al., 2009b). Additionally, TNF-a 308 and 238 pro-
moter gene polymorphisms have been reported to be associ-
ated with several autoimmune disorders including Systemic
Lupus Erythematosus, Rheumatoid Arthritis and infections
such as tuberculosis (Qidwai and Khan, 2011). Inflammation
with high levels of pro-inflammation cytokines such as IL-1,
IL-6 and TNF-a is a key feature of T2DM. These observations
suggest that TNF-a plays a role in the pathogenicity of T2DM
and obesity (Feng et al., 2011).
We also found some reports documenting the significance
of the SNPs in 308G/A and 238G/A in the promoter of
the gene encoding TNF-a in the risk of diabetes/insulin resis-
tance development in subjects aged 40–60 years (Elsaid et al.,Please cite this article in press as: Jamil, K. et al., TNF-alpha 308G/A and 238G/A
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05.2012; Fontaine-Bisson et al., 2007) and 85 years (Heijmans
et al., 2002). Also, homozygosity for A-allele conferred a more
than fourfold increased risk of diabetes. Hence, we took up
bioinformatic studies to test our hypothesis of how TNF-a
could influence the disease condition. The TNF gene is located
in the HLA region characterized by strong linkage disequilib-
rium. Some studies have reported the lack of association of
TNF-a (14 alleles) and the TNFc (2 alleles) short tandem
repeats with the risk of diabetes despite their strong linkage
disequilibrium with the 308G/A promoter polymorphism
(Heijmans et al., 2002). Although this makes it difficult to cat-
egorically establish that the 308G/A polymorphism alone is
the functional variation in association with diabetes, neverthe-
less this information formed an attractive candidate for
investigation.
Results obtained through our in silico studies clearly iden-
tified three novel targets in T2DM-BIRC2, BIRC3 and
RIPK1, through computational analysis of TNF-a protein
network. Their hubness in a network enriched in proteins
deregulated in diseases suggests that they may also play a role
in diabetes mellitus, via their associations, contributing to
pathogenesis mechanisms such as lowered insulin production,
development of insulin resistance or diabetic nephropathy.
Our network analysis also showed the interconnectivity
between signaling pathways such as TNF receptor, NFjB,
Toll-like receptor, apoptosis, etc.; this information could be
essential in understanding disease mechanisms, especially in
complex diseases such as diabetes, wherein multiple pathways
are co-operatively engaged in pathogenesis of the disease. Fur-
ther, our analysis of the hub proteins in the network has high-
lighted proteins that may act as crucial nodes, in synergism
with TNF-a, in attributing insulin resistance to T2DM
patients. Thus, the association of several proteins with TNF-
a, observed in the protein interaction network, suggests a
key role for these interactions in normal biological processes
mediated by this protein and its signaling network. These pro-
teins may be of significance in diabetes, wherein they may
assist TNF-a in deregulation of pathways necessary to main-
tain insulin production, sensitivity and regulation of glucose
levels and also in deregulation of pathways that lead to patho-
genesis of diabetes induced/associated complications such as
nephropathies and end stage renal disease. In conclusion,
our study predicts the possible pathways that may contribute
to TNF-a-mediated T2DM pathogenesis.
5. Conclusion
Despite the rapid progress in identifying diabetes related genes,
what the precise causal variants are and how these variants
increase susceptibility to type 2 diabetes mellitus (T2DM)
remain unknown. However, we have identified new targets
for T2DM using various Bioinformatics tools, as the promoter
region polymorphisms did not show strong association with
T2DM.
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